Streetbeat News

COEP

Coeptis Therapeutics Holdings Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

0.19

Mkt cap

7.9M

Volume

634K

High

0.20

P/E Ratio

-0.68

52-wk high

0.97

Low

0.18

Div yield

N/A

52-wk low

0.15

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, enhancing its capabilities with AI-powered marketing and robotic process automation. This acquisition aims to drive innovation, operational efficiency, and growth opportunities.

Portfolio Pulse from

December 03, 2024 | 1:30 pm

Coeptis Therapeutics announced that Phase 1 data on their COVID-19 treatment, DVX201, has been accepted for publication. The study shows the safety and feasibility of using allogeneic NK cells in high-risk COVID-19 patients, with no significant toxicities observed.

Portfolio Pulse from

November 07, 2024 | 1:30 pm

Coeptis Therapeutics has expanded its license agreement with Deverra Therapeutics to include the use of unmodified NK cells for pandemic preparedness and emergency use. This expansion allows Coeptis to use these cells in treating viral infections and pandemic-related illnesses, as well as for emergency stockpiling.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:20 pm

Coeptis Therapeutics has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq exchange until January 15, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:24 am

Coeptis Therapeutics has completed its Phase 1 trial for COVID-19-related infections and is advancing its cell therapy platforms. The company raised $5.6 million in capital and is appealing a Nasdaq delisting decision. Strategic partnerships and new developments in cell therapy are key growth drivers.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:19 pm

Digital Turbine (APPS) shares surged over 20% in pre-market trading after reporting better-than-expected quarterly results. Other notable pre-market movers include Expion360 (XPON), Anew Medical (WENA), Luxurban Hotels (LUXH), Coeptis Therapeutics (COEP), Aspen Aerogels (ASPN), Sezzle (SEZL), Color Star Technology (ADD), Fluence Energy (FLNC), and Staffing 360 Solutions (STAF) among gainers. Losers include Cardlytics (CDLX), Outset Medical (OM), Bumble (BMBL), Viracta Therapeutics (VIRX), Greenlane Holdings (GNLN), JFrog (FROG), Know Labs (KNW), Dutch Bros (BROS), Fastly (FSLY), and Precigen (PGEN).

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 10:02 am

In Wednesday's pre-market session, several health care stocks experienced significant movements. Mustang Bio (MBIO) saw a 51.6% increase, while NeuroBo Pharmaceuticals (NRBO) rose by 30.78%. Rezolute (RZLT) and Akso Health Group (AHG) also saw gains of 25.0% and 16.26%, respectively. On the losing side, LifeStance Health Group (LFST) declined by 18.6%, and Lipella Pharmaceuticals (LIPO) fell by 11.84%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 12:06 pm

Coeptis Therapeutics announced it will present its universal allogeneic SNAP-CAR NK cell therapy at the International Society for Cell & Gene Therapy (ISCT) 2024 conference, scheduled from May 28 to June 1.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:56 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Orgenesis, AN2 Therapeutics, GRI Bio, NuCana, Stoke Therapeutics, and Candel Therapeutics were among the gainers, with increases ranging from 4.99% to 8.5%. On the downside, Acorda Therapeutics, Aesthetic Medical Intl, Eiger BioPharmaceuticals, Coeptis Therapeutics, iSpecimen, and WAVE Life Sciences experienced declines between 4.96% and 8.9%. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 8:31 pm

In Tuesday's after-market session, several healthcare stocks showed notable movements. Apollomics, Cara Therapeutics, Coeptis Therapeutics, Titan Pharma, BioSig Technologies, and Iridex were among the gainers, with increases ranging from 5.52% to 10.9%. On the downside, Akili, Mira Pharmaceuticals, Estrella Immunopharma, Virpax Pharmaceuticals, United Therapeutics, and ProSomnus experienced declines between 6.46% and 22.9%. Iridex and ProSomnus also released their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.